Oral epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of non-small cell lung cancer: Comparative pharmacokinetics and drug-drug interactions

Cancer Treatment Reviews

Volumn 40, Issue 8, 2014, Pages 917-926

  Peters, Solange ^a   Zimmermann, Stefan ^a   Adjei, Alex A ^b  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^b ROSWELL PARK CANCER INSTITUTE   (United States)

Author keywords

Afatinib; Chemotherapy; Dacomitinib; Epidermal growth factor receptor; Erlotinib; Gefitinib; Non small cell lung cancer; Pharmacokinetics; Tyrosine kinase inhibitors

Indexed keywords

AFATINIB; ANTACID AGENT; BREAST CANCER RESISTANCE PROTEIN; CREATININE; CYCLOSPORIN; CYTOCHROME P450 1A1; CYTOCHROME P450 1A2; CYTOCHROME P450 1B1; CYTOCHROME P450 2D6; CYTOCHROME P450 3A4; CYTOCHROME P450 3A5; DACOMITINIB; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; GEFITINIB; HISTAMINE H2 RECEPTOR ANTAGONIST; MULTIDRUG RESISTANCE PROTEIN 1; MULTIDRUG RESISTANCE PROTEIN 2; NERATINIB; PAROXETINE; PHENYTOIN; PROTON PUMP INHIBITOR; RITONAVIR; SIMVASTATIN; VERAPAMIL;

AREA UNDER THE CURVE; CREATININE CLEARANCE; DISTRIBUTION VOLUME; DRUG ABSORPTION; DRUG BILE LEVEL; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG FECES LEVEL; DRUG GLUCURONIDATION; DRUG HALF LIFE; DRUG METABOLISM; DRUG OXIDATION; DRUG PROTEIN BINDING; DRUG SOLUBILITY; DRUG TOLERABILITY; DRUG URINE LEVEL; ENZYME INDUCTION; ERYTHROCYTE LEVEL; FOOD DRUG INTERACTION; GENETIC POLYMORPHISM; HEPATITIS; HUMAN; LIVER CIRRHOSIS; LIVER METASTASIS; LUNG NON SMALL CELL CANCER; MAXIMUM PLASMA CONCENTRATION; MILD RENAL IMPAIRMENT; MODERATE RENAL IMPAIRMENT; PHARMACOGENETICS; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PLASMA CONCENTRATION-TIME CURVE; REVIEW; SMOKING; STEADY STATE; STOMACH PH; TISSUE DISTRIBUTION;

AFATINIB; CHEMOTHERAPY; DACOMITINIB; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; GEFITINIB; NON-SMALL CELL LUNG CANCER; PHARMACOKINETICS; TYROSINE KINASE INHIBITORS;

ADMINISTRATION, ORAL; CARCINOMA, NON-SMALL-CELL LUNG; DRUG INTERACTIONS; HUMANS; LUNG NEOPLASMS; PROTEIN KINASE INHIBITORS; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 84904810695     PISSN: 03057372     EISSN: 15321967     Source Type: Journal    
DOI: 10.1016/j.ctrv.2014.06.010     Document Type: Review

References (126)

1. Pao W., Girard N. New driver mutations in non-small-cell lung cancer. Lancet Oncol 2011, 12:175-180.
2. Cataldo V.D., Gibbons D.L., Perez-Soler R., Quintas-Cardama A. Treatment of non-small-cell lung cancer with erlotinib or gefitinib. N Engl J Med 2011, 364:947-955.
3. Arteaga C.L. Epidermal growth factor receptor dependence in human tumors: more than just expression?. Oncologist 2002, 7(Suppl. 4):31-39.
4. Ciardiello F., Tortora G. EGFR antagonists in cancer treatment. N Engl J Med 2008, 358:1160-1174.
5. Sharma S.V., Bell D.W., Settleman J., Haber D.A. Epidermal growth factor receptor mutations in lung cancer. Nat Rev Cancer 2007, 7:169-181.
6. Mok T.S., Wu Y.L., Thongprasert S., et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009, 361:947-957.
7. Maemondo M., Inoue A., Kobayashi K., et al. North-East Japan study group. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 2010, 362:2380-2388.
8. Mitsudomi T., Morita S., Yatabe Y., et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol 2010, 11:121-128.
9. Zhou C., Wu Y.L., Chen G., et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol 2011, 12:735-742.
10. Rosell R., Carcereny E., Gervais R., et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol 2012, 13:239-246.
11. Thatcher N., Chang A., Parikh P., et al. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa survival evaluation in lung cancer). Lancet 2005, 366:1527-1537.
12. Tarceva [package insert] (2014) Genentech USA, Inc., South San Francisco, CA.
13. European Medicines Agency. Tarceva. Summary of Product Characteristics, 3 February 2014. Accessed at . [20 Feb 2014]. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000618/WC500033994.pdf.
14. Sequist LV, Waltman BA, Dias-Santagata D, et al. Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci Transl Med 2011;3:75ra26.
15. Yu H.A., Arcila M.E., Rekhtman N., et al. Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers. Clin Cancer Res 2013, 19:2240-2247.
16. Kosaka T., Yatabe Y., Endoh H., et al. Analysis of epidermal growth factor receptor gene mutation in patients with non-small cell lung cancer and acquired resistance to gefitinib. Clin Cancer Res 2006, 12:5764-5769.
17. Yun C.H., Mengwasser K.E., Toms A.V., et al. The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP. Proc Natl Acad Sci USA 2008, 105:2070-2075.
18. Reid A., Vidal L., Shaw H., de Bono J. Dual inhibition of ErbB1 (EGFR/HER1) and ErbB2 (HER2/neu). Eur J Cancer 2007, 43:481-489.
19. Boehringer Ingelheim. Gilotrif [prescribing information] (2014) Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT. [17 May 2014]. http://www.gilotrif.com/.
20. European Medicines Agency. Giotrif. Summary of Product Characteristics, 16 October 2013. [20 Feb 2014]. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002280/WC500152392.pdf.
21. Miller V.A., Hirsh V., Cadranel J., et al. Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial. Lancet Oncol 2012, 13:528-538.
22. Katakami N., Atagi S., Goto K., et al. LUX-Lung 4: A phase II trial of afatinib in patients with advanced non-small-cell lung cancer who progressed during prior treatment with erlotinib, gefitinib, or both. J Clin Oncol 2013, 31:3335-3341.
23. Schuler MH, Yang JC, Park K, et al. Continuation of afatinib beyond progression: Results of a randomized, open-label, phase III trial of afatanib plus paclitaxel (P) versus investigator's choice chemotherapy (CT) in patients (pts) with metastatic non-small cell lung cancer (NSCLC) progressed on erlotinib/gefitinib (E/G) and afatanib-LUX-Lung 5 (LL5). J Clin Oncol 2014;32(Suppl):abstract 8019.
24. Yang J.C., Shih J.Y., Su W.C., et al. Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (LUX-Lung 2): a phase 2 trial. Lancet Oncol 2012, 13:539-548.
25. Sequist L.V., Yang J.C., Yamamoto N., et al. Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J Clin Oncol 2013, 31:3327-3334.
26. Wu Y.L., Zhou C., Hu C.P., et al. Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial. Lancet Oncol 2014, 15:213-222.
27. Yang JC, Sequist LV, Schuler MH, et al. Overall survival (OS) in patients (pts) with advanced non-small cell lung cancer (NSCLC) harboring common (Del19/L858R) epidermal growth factor receptor mutations (EGFR mut): Pooled analysis of two large open-label phase III studies (LUX-Lung 3 [LL3] and LUX-Lung 6 [LL6]) comparing afatinib with chemotherapy (CT). J Clin Oncol 2014;32(Suppl):abstract 8046.
28. Ramalingam S.S., Blackhall F., Krzakowski M., et al. Randomized phase II study of dacomitinib (PF-00299804), an irreversible pan-human epidermal growth factor receptor inhibitor, versus erlotinib in patients with advanced non-small-cell lung cancer. J Clin Oncol 2012, 30:3337-3344.
29. Reckamp K.L., Giaccone G., Camidge D.R., et al. A phase 2 trial of dacomitinib (PF-00299804), an oral, irreversible pan-HER (human epidermal growth factor receptor) inhibitor, in patients with advanced non-small cell lung cancer after failure of prior chemotherapy and erlotinib. Cancer 2014, 120:1145-1154.
30. Kris MG, Mok T, Ignatius OSH, et al. First-line dacomitinib (PF-00299804), an irreversible pan-HER tyrosine kinase inhibitor, for patients with EGFR-mutant lung cancers. J Clin Oncol 2012;30(Suppl):abstract 7530.
31. Park K, Heo DS, Cho B, et al. PF-00299804 (PF299) in Asian patients (pts) with non-small cell lung cancer (NSCLC) refractory to chemotherapy (CT) and erlotinib (E) or gefitinib (G): A phase (P) I/II study. J Clin Oncol 2010;28(Suppl):abstract 7599.
32. Ramalingam SS, Jänne PA, Mok T, et al. Randomized, double-blinded study of dacomitinib, an irreversible pan-human epidermal growth factor receptor (HER) inhibitor, versus erlotinib for second-line/third-line therapy of locally advanced/metastatic non-small cell lung cancer (ARCHER 1009). J Clin Oncol 2014;32(Suppl):abstract 8018.
33. Ellis PM, Liu G, Millward M, et al. NCIC CTG BR.26: A phase III randomized, double blind, placebo controlled trial of dacomitinib versus placebo in patients with advanced/metastatic non-small cell lung cancer (NSCLC) who received prior chemotherapy and an EGFR TKI. J Clin Oncol 2014;32(Suppl):abstract 8036.
34. Sequist L.V., Besse B., Lynch T.J., et al. Neratinib, an irreversible pan-ErbB receptor tyrosine kinase inhibitor: results of a phase II trial in patients with advanced non-small-cell lung cancer. J Clin Oncol 2010, 28:3076-3083.
35. Gandhi L., Bahleda R., Tolaney S.M., et al. Phase I study of neratinib in combination with temsirolimus in patients with human epidermal growth factor receptor 2-dependent and other solid tumors. J Clin Oncol 2014, 32:68-75.
36. Gandhi L, Soria J-C, Bryce R, Besse B. Randomized phase II study of neratinib with or without temsirolimus in patients (pts) with non-small cell lung cancer (NSCLC) carrying HER2-activating mutations. J Clin Oncol 2013;31(Suppl):abstract TPS8124.
37. Cross DA, Ashton SE, Ghiorghiu S, et al. AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer. Cancer Discov 2014;Jun 3. pii: CD-14-0337. [Epub ahead of print].
38. Walter A.O., Sjin R.T., Haringsma H.J., et al. Discovery of a mutant-selective covalent inhibitor of EGFR that overcomes T790M-mediated resistance in NSCLC. Cancer Discov 2013, 3:1404-1415.
39. Tjin Tham Sjin R, Lee K, Walter AO, et al. In vitro and in vivo characterization of irreversible mutant-selective EGFR inhibitors that are wild-type sparing. Mol Cancer Ther 2014; 2014;13:1468-79.
40. Kim D.W., Kim S.W., Kim T.M., et al. Phase I study of HM61713, a novel epidermal growth factor receptor (EGFR) mutant selective inhibitor, in non-small cell lung cancer (NSCLC) patients having an activating EGFR mutation but failed to prior EGFR tyrosine kinase inhibitor (TKI) therapy (abstract). J Thorac Oncol 2013, 8:S892-S893.
41. Jänne PA, Ramalingam SS, Yang JC, Ahn MJ, Kim DW. Clinical activity of the mutant-selective EGFR inhibitor AZD9291 in patients (pts) with EGFR inhibitor-resistant non-small cell lung cancer (NSCLC). J Clin Oncol 2014;32(Suppl):abstract 8009.
42. Sequist LV, Soria J-C, Gadgeel SM, et al. First-in-human evaluation of CO-1686, an irreversible, highly selective tyrosine kinase inhibitor of mutations of EGFR (activating and T790M). J Clin Oncol 2014;32(Suppl):abstract 8010.
43. Kim DW, Lee DH, Kang JH, Park K, Han JY. Clinical activity and safety of HM61713, an EGFR-mutant selective inhibitor, in advanced non-small cell lung cancer (NSCLC) patients (pts) with EGFR mutations who had received EGFR tyrosine kinase inhibitors (TKIs). J Clin Oncol 2014;32(Suppl):abstract 8011.
44. Kitagawa D., Yokota K., Gouda M., et al. Activity-based kinase profiling of approved tyrosine kinase inhibitors. Genes Cells 2013, 18:110-122.
45. Li D., Ambrogio L., Shimamura T., et al. BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models. Oncogene 2008, 27:4702-4711.
46. Solca F., Dahl G., Zoephel A., et al. Target binding properties and cellular activity of afatinib (BIBW 2992), an irreversible ErbB family blocker. J Pharmacol Exp Ther 2012, 343:342-350.
47. Engelman J.A., Zejnullahu K., Gale C.M., et al. PF00299804, an irreversible pan-ERBB inhibitor, is effective in lung cancer models with EGFR and ERBB2 mutations that are resistant to gefitinib. Cancer Res 2007, 67:11924-11932.
48. Gonzales A.J., Hook K.E., Althaus I.W., et al. Antitumor activity and pharmacokinetic properties of PF-00299804, a second-generation irreversible pan-erbB receptor tyrosine kinase inhibitor. Mol Cancer Ther 2008, 7:1880-1889.
49. Chong C.R., Jänne P.A. The quest to overcome resistance to EGFR-targeted therapies in cancer. Nat Med 2013, 19:1389-1400.
50. Swaisland H., Laight A., Stafford L., et al. Pharmacokinetics and tolerability of the orally active selective epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in healthy volunteers. Clin Pharmacokinet 2001, 40:297-306.
51. Swaisland H.C., Smith R.P., Laight A., et al. Single-dose clinical pharmacokinetic studies of gefitinib. Clin Pharmacokinet 2005, 44:1165-1177.
52. European Medicines Agency. Iressa (gefitinib) Assessment Report, July 2009. [20 Feb 2014]. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/001016/WC500036361.pdf.
53. Frohna P., Lu J., Eppler S., et al. Evaluation of the absolute oral bioavailability and bioequivalence of erlotinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in a randomized, crossover study in healthy subjects. J Clin Pharmacol 2006, 46:282-290.
54. Wind S., Schmid M., Erhardt J., Goeldner R.G., Stopfer P. Pharmacokinetics of afatinib, a selective irreversible ErbB family blocker, in patients with advanced solid tumours. Clin Pharmacokinet 2013, 52:1101-1109.
55. Yap T.A., Vidal L., Adam J., et al. Phase I trial of the irreversible EGFR and HER2 kinase inhibitor BIBW 2992 in patients with advanced solid tumors. J Clin Oncol 2010, 28:3965-3972.
56. European Medicines Agency. Committee for Medicinal Products for Human Use (CHMP) Assessment Report for Giotrif (afatinib). 16 October 2013. [20 Feb 2014]. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/002280/WC500152394.pdf.
57. Giri N, LaBadie RR, Liang Y, et al. Absolute bioavailability of dacomitinib (PF-00299804): Comparison of oral and intravenous administration in healthy volunteers. Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego, CA. Philadelphia (PA): Abstract CT208.
58. Jänne P.A., Boss D.S., Camidge D.R., et al. Phase I dose-escalation study of the pan-HER inhibitor, PF299804, in patients with advanced malignant solid tumors. Clin Cancer Res 2011, 17:1131-1139.
59. Ruiz-Garcia A., Masters J.C., LaBadie R.R., et al. Effect of food and antacid treatment on bioavailability of 45 mg tablet of dacomitinib relative to dacomitinib administration under fasted conditions (abstract PII-007). Clin Pharmacol Ther 2014, 95:S63.
60. Sequist LV, Soria JC, Gadgeel SM, et al. First-in-human evaluation of CO-1686, an irreversible, selective, and potent tyrosine kinase inhibitor of EGFR T790M. J Clin Oncol 2013;31(Suppl):abstract 2524.
61. McKillop D., Hutchison M., Partridge E.A., et al. Metabolic disposition of gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, in rat, dog and man. Xenobiotica 2004, 34:917-934.
62. Lu J.F., Eppler S.M., Wolf J., et al. Clinical pharmacokinetics of erlotinib in patients with solid tumors and exposure-safety relationship in patients with non-small cell lung cancer. Clin Pharmacol Ther 2006, 80:136-145.
63. 14C] dacomitinib (PF-00299804) in healthy male volunteers. Cancer Chemother Pharmacol 2013, 72:379-385.
64. Schnell D, Buschke S, Fuchs H, et al. Pharmacokinetics of afatinib in subjects with mild or moderate hepatic impairment. Cancer Chemother Pharmacol 2014;Jun 7. [Epub ahead of print].
65. Johnson J.R., Cohen M., Sridhara R., et al. Approval summary for erlotinib for treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of at least one prior chemotherapy regimen. Clin Cancer Res 2005, 11:6414-6421.
66. Stopfer P., Marzin K., Narjes H., et al. Afatinib pharmacokinetics and metabolism after oral administration to healthy male volunteers. Cancer Chemother Pharmacol 2012, 69:1051-1061.
67. McKillop D., McCormick A.D., Millar A., et al. Cytochrome P450-dependent metabolism of gefitinib. Xenobiotica 2005, 35:39-50.
68. European Medicines Agency. Iressa (gefitinib). Summary of Product Characteristics. 30 July 2013. [20 Feb 2014]. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/001016/WC500036358.pdf.
69. Ling J., Johnson K.A., Miao Z., et al. Metabolism and excretion of erlotinib, a small molecule inhibitor of epidermal growth factor receptor tyrosine kinase, in healthy male volunteers. Drug Metab Dispos 2006, 34:420-426.
70. Li J., Zhao M., He P., Hidalgo M., Baker S.D. Differential metabolism of gefitinib and erlotinib by human cytochrome P450 enzymes. Clin Cancer Res 2007, 13:3731-3737.
71. Petros W.P., Younis I.R., Ford J.N., Weed S.A. Effects of tobacco smoking and nicotine on cancer treatment. Pharmacotherapy 2012, 32:920-931.
72. Hamilton M., Wolf J.L., Rusk J., et al. Effects of smoking on the pharmacokinetics of erlotinib. Clin Cancer Res 2006, 12:2166-2171.
73. Horak J., White J., Harris A.L., et al. The effect of different etiologies of hepatic impairment on the pharmacokinetics of gefitinib. Cancer Chemother Pharmacol 2011, 68:1485-1495.
74. Freiwald M., Schmid U., Fleury A., et al. Population pharmacokinetics of afatinib, an irreversible ErbB family blocker, in patients with various solid tumors. Cancer Chemother Pharmacol 2014, 73:759-770.
75. O'Bryant C.L., Haluska P., Rosen L., et al. An open-label study to describe pharmacokinetic parameters of erlotinib in patients with advanced solid tumors with adequate and moderately impaired hepatic function. Cancer Chemother Pharmacol 2012, 69:605-612.
76. Giri N, Plotka A, Liang Y, et al. Influence of mild and moderate hepatic impairment on the pharmacokinetics (PK) of the pan-HER inhibitor dacomitinib. J Clin Oncol 2013;31(Suppl):abstract 2568.
77. Lin J.H., Yamazaki M. Role of P-glycoprotein in pharmacokinetics: clinical implications. Clin Pharmacokinet 2003, 42:59-98.
78. Mizuno N., Niwa T., Yotsumoto Y., Sugiyama Y. Impact of drug transporter studies on drug discovery and development. Pharmacol Rev 2003, 55:425-461.
79. Marzolini C., Paus E., Buclin T., Kim R.B. Polymorphisms in human MDR1 (P-glycoprotein): recent advances and clinical relevance. Clin Pharmacol Ther 2004, 75:13-33.
80. Oostendorp R.L., Beijnen J.H., Schellens J.H. The biological and clinical role of drug transporters at the intestinal barrier. Cancer Treat Rev 2009, 35:137-147.
81. van Erp N.P., Gelderblom H., Guchelaar H.J. Clinical pharmacokinetics of tyrosine kinase inhibitors. Cancer Treat Rev 2009, 35:692-706.
82. Li J., Cusatis G., Brahmer J., et al. Association of variant ABCG2 and the pharmacokinetics of epidermal growth factor receptor tyrosine kinase inhibitors in cancer patients. Cancer Biol Ther 2007, 6:432-438.
83. Shi Z., Peng X.X., Kim I.W., et al. Erlotinib (Tarceva, OSI-774) antagonizes ATP-binding cassette subfamily B member 1 and ATP-binding cassette subfamily G member 2-mediated drug resistance. Cancer Res 2007, 67:11012-11020.
84. Marchetti S., de Vries N.A., Buckle T., et al. Effect of the ATP-binding cassette drug transporters ABCB1, ABCG2, and ABCC2 on erlotinib hydrochloride (Tarceva) disposition in in vitro and in vivo pharmacokinetic studies employing Bcrp1-/-/Mdr1a/1b-/- (triple-knockout) and wild-type mice. Mol Cancer Ther 2008, 7:2280-2287.
85. Wind S., Giessmann T., Jungnik A., et al. Pharmacokinetic drug interactions of afatinib with rifampicin and ritonavir. Clin Drug Invest 2014, 34:173-182.
86. Visentin M., Biason P., Toffoli G. Drug interactions among the epidermal growth factor receptor inhibitors, other biologics and cytotoxic agents. Pharmacol Ther 2010, 128:82-90.
87. Swaisland H.C., Ranson M., Smith R.P., et al. Pharmacokinetic drug interactions of gefitinib with rifampicin, itraconazole and metoprolol. Clin Pharmacokinet 2005, 44:1067-1081.
88. Chhun S., Verstuyft C., Rizzo-Padoin N., et al. Gefitinib-phenytoin interaction is not correlated with the C-erythromycin breath test in healthy male volunteers. Br J Clin Pharmacol 2009, 68:226-237.
89. European Medicines Agency. Tarceva (erlotinib) Assessment Report, July 2005. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Scientific_Discussion/human/000618/WC500033991.pdf [20 Feb 2014].
90. Rakhit A., Pantze M.P., Fettner S., et al. The effects of CYP3A4 inhibition on erlotinib pharmacokinetics: computer-based simulation (SimCYP) predicts in vivo metabolic inhibition. Eur J Clin Pharmacol 2008, 64:31-41.
91. Hamilton M., Wolf J.L., Drolet D.W., et al. The effect of rifampicin, a prototypical CYP3A4 inducer, on erlotinib pharmacokinetics in healthy subjects. Cancer Chemother Pharmacol 2014, 73:613-621.
92. Tran H.T., Zinner R.G., Blumenschein G.R., et al. Pharmacokinetic study of the phase III, randomized, double-blind, multicenter trial (TRIBUTE) of paclitaxel and carboplatin combined with erlotinib or placebo in patients with advanced non-small cell lung cancer (NSCLC). Invest New Drugs 2011, 29:499-505.
93. Thomas K.S., Billingsley A., Amarshi N., Nair B.A. Elevated international normalized ratio associated with concomitant warfarin and erlotinib. Am J Health Syst Pharm 2010, 67:1426-1429.
94. Grenader T., Gipps M., Shavit L., Gabizon A. Significant drug interaction: phenytoin toxicity due to erlotinib. Lung Cancer 2007, 57:404-406.
95. Veeraputhiran M., Sundermeyer M. Rhabdomyolysis resulting from pharmacologic interaction between erlotinib and simvastatin. Clin Lung Cancer 2008, 9:232-234.
96. Carcelero E., Anglada H., Tuset M., Creus N. Interactions between oral antineoplastic agents and concomitant medication: a systematic review. Expert Opin Drug Saf 2013, 12:403-420.
97. Bello C.L., LaBadie R.R., Ni G., et al. The effect of dacomitinib (PF-00299804) on CYP2D6 activity in healthy volunteers who are extensive or intermediate metabolizers. Cancer Chemother Pharmacol 2012, 69:991-997.
98. Ruiz-Garcia A., Giri N., LaBadie R.R., et al. A phase I open-label study to investigate the potential drug-drug interaction between single-dose dacomitinib and steady-state paroxetine in healthy volunteers. J Clin Pharmacol 2014, 54:555-562.
99. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al. National Cancer Institute of Canada Clinical Trials Group. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005;353:123-32.
100. Hilton J.F., Tu D., Seymour L., Shepherd F.A., Bradbury P.A. An evaluation of the possible interaction of gastric acid suppressing medication and the EGFR tyrosine kinase inhibitor erlotinib. Lung Cancer 2013, 82:136-142.
101. Saeki S., Sasaki J., Sakata S., et al. The influence of gastric secretion inhibitors on gefitinib therapy in patients with nonsmall cell lung cancer (abstract P3.176). J Thor Oncol 2011, 6(Suppl. 2):S1282-S1283.
102. Saeki S, Sasaki J, Morioka J, et al. The influence of gastric secretion inhibitors on gefitinib therapy in patients with non-small cell lung cancer harboring epidermal growth factor receptor activating mutations. J Clin Oncol 2012;30(Suppl):abstract e18059.
103. Hamilton M., Wolf J.L., Zborowski D., et al. TarcevaTM (erlotinib) exposure/effects (EE) analysis from a Phase III study in advanced NSCLC: effect of smoking on the PK of erlotinib (abstract 6155). Pro Am Assoc Cancer Res 2005, 46:1451.
104. Hughes A.N., O'Brien M.E., Petty W.J., et al. Overcoming CYP1A1/1A2 mediated induction of metabolism by escalating erlotinib dose in current smokers. J Clin Oncol 2009, 27:1220-1226.
105. Smit EF, Gervais R, Zhou C, et al. Efficacy and safety results from CurrentS, a double-blind, randomized, phase III study of second-line erlotinib (150mg versus 300mg) in current smokers with advanced non-small cell lung cancer (NSCLC). J Clin Oncol 2014;32(Suppl):abstract 8046.
106. Swaisland H.C., Cantarini M.V., Fuhr R., Holt A. Exploring the relationship between expression of cytochrome P450 enzymes and gefitinib pharmacokinetics. Clin Pharmacokinet 2006, 45:633-644.
107. Rudin C.M., Liu W., Desai A., et al. Pharmacogenomic and pharmacokinetic determinants of erlotinib toxicity. J Clin Oncol 2008, 26:1119-1127.
108. Hirsh V. Managing treatment-related adverse events associated with EGFR tyrosine kinase inhibitors in advanced non-small-cell lung cancer. Curr Oncol 2011, 18:126-138.
109. Yang J.C., Sequist L., O'Byrne K., et al. Epidermal growth factor receptor (EGFR)-mediated adverse events (AEs) in patients (pts) with EGFR mutation positive (EGFR M+) non-small cell lung cancer treated with afatinib (abstract 895). Eur J Cancer 2013, 49(Suppl. 2):S190.
110. Lucchini E., Pilotto S., Spada E., et al. Targeting the epidermal growth factor receptor in solid tumors: focus on safety. Expert Opin Drug Saf 2014, 13:535-549.
111. D'Arcangelo M., Hirsch F.R. Clinical and comparative utility of afatinib in non-small cell lung cancer. Biologics 2014, 8:183-192.
112. Bruno R., Mass R.D., Jones C., Lu J.F., Wine E. Preliminary population pharmacokinetics (PPK) and exposure-safety (E-S) relationships of erlotinib HCL in patients with metastatic breast cancer (MBC) (abstract 823). Proc Am Soc Clin Oncol 2003, 22:205.
113. Thomas F., Rochaix P., White-Koning M., et al. Population pharmacokinetics of erlotinib and its pharmacokinetic/pharmacodynamic relationships in head and neck squamous cell carcinoma. Eur J Cancer 2009, 45:2316-2323.
114. Tiseo M., Andreoli R., Gelsomino F., et al. Correlation between erlotinib pharmacokinetics, cutaneous toxicity and clinical outcomes in patients with advanced non-small cell lung cancer (NSCLC). Lung Cancer 2014, 83:265-271.
115. Petrelli F., Borgonovo K., Cabiddu M., Lonati V., Barni S. Relationship between skin rash and outcome in non-small-cell lung cancer patients treated with anti-EGFR tyrosine kinase inhibitors: a literature-based meta-analysis of 24 trials. Lung Cancer 2012, 78:8-15.
116. Rukazenkov Y., Speake G., Marshall G., et al. Epidermal growth factor receptor tyrosine kinase inhibitors: similar but different?. Anticancer Drugs 2009, 20:856-866.
117. ter Heine R., Fanggiday J.C., Lankheet N.A., et al. Erlotinib and pantoprazole: a relevant interaction or not?. Br J Clin Pharmacol 2010, 70:908-911.
118. Budha N.R., Frymoyer A., Smelick G.S., et al. Drug absorption interactions between oral targeted anticancer agents and PPIs: is pH-dependent solubility the Achilles heel of targeted therapy?. Clin Pharmacol Ther 2012, 92:203-213.
119. Smelick G.S., Heffron T.P., Chu L., et al. Prevalence of acid-reducing agents (ARA) in cancer populations and ARA drug-drug interaction potential for molecular targeted agents in clinical development. Mol Pharm 2013, 10:4055-4062.
120. Ranson M., Hammond L.A., Ferry D., et al. ZD1839, a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumors: results of a phase I trial. J Clin Oncol 2002, 20:2240-2250.
121. Takahashi T., Boku N., Murakami H., et al. Phase I and pharmacokinetic study of dacomitinib (PF-00299804), an oral irreversible, small molecule inhibitor of human epidermal growth factor receptor-1, -2, and -4 tyrosine kinases, in Japanese patients with advanced solid tumors. Invest New Drugs 2012, 30:2352-2363.
122. Li J., Brahmer J., Messersmith W., Hidalgo M., Baker S.D. Binding of gefitinib, an inhibitor of epidermal growth factor receptor-tyrosine kinase, to plasma proteins and blood cells: in vitro and in cancer patients. Invest New Drugs 2006, 24:291-297.
123. Ranson M., Shaw H., Wolf J., et al. A phase I dose-escalation and bioavailability study of oral and intravenous formulations of erlotinib (Tarceva, OSI-774) in patients with advanced solid tumors of epithelial origin. Cancer Chemother Pharmacol 2010, 66:53-58.
124. Ling J., Fettner S., Lum B.L., Riek M., Rakhit A. Effect of food on the pharmacokinetics of erlotinib, an orally active epidermal growth factor receptor tyrosine-kinase inhibitor, in healthy individuals. Anticancer Drugs 2008, 19:209-216.
125. Li J., Karlsson M.O., Brahmer J., et al. CYP3A phenotyping approach to predict systemic exposure to EGFR tyrosine kinase inhibitors. J Natl Cancer Inst 2006, 98:1714-1723.
126. Shah R.R., Morganroth J., Shah D.R. Cardiovascular safety of tyrosine kinase inhibitors: with a special focus on cardiac repolarisation (QT interval). Drug Saf 2013, 36:295-316.